Drug details

Columvi (glofitamab-gxbm injection)

type of Antineoplastics, Anti-CD20 Monoclonal Antibodies

Columvi (glofitamab-gxbm) is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.

This drug may have the following side effects:

• rash,
• musculoskeletal pain,
• fatigue,
• cytokine release syndrome,
• decreased white blood cells (lymphocytes, neutrophils),
• decreased phosphate,
• increased uric acid, and
• decreased fibrinogen.

The following drugs are related to Columvi, either as a replacement or used together:

• Calquence (acalabrutinib capsules)
• Velcade (bortezomib)
• Brukinsa (zanubrutinib capsules)
• Jaypirca (pirtobrutinib tablets)
• Venclexta (venetoclax tablets)